Avicella Capital
Avicella Capital, established in 2024, is a U.S.-based venture capital firm specializing in healthcare investments. It focuses on identifying and financing innovative, ethically-driven ventures that aim to improve patient outcomes and elevate healthcare standards. The firm concentrates on sectors such as therapeutics, medical devices, diagnostics, and health technology.
2 past transactions
Convergence Medical Robotics
Series A in 2025
Convergence Medical Robotics is a Brisbane-based pre-clinical medical robotics company making arthroscopy better through the invention of the V01 Robot. It solves the complexity of arthroscopy by creating the world's first arthroscopic robot.
Kinoxis Therapeutics
Series B in 2024
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.